Active ingredientTerazosin HClCat. No. P-T056-001CAS 63074-08-8Family · Pharmaceutical analytical standards
Terazosin
An alpha-1 blocker that relaxes the muscle of blood vessels and the prostate: approved in the United States in 1987 for hypertension, since the early 1990s it has also been used for the urinary symptoms of benign prostatic hyperplasia. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.
Did you know?In 2019 researchers at the University of Iowa and in Beijing showed that, by activating the enzyme PGK1 and boosting the energy produced by cells, it slows neurodegeneration in models of Parkinson's disease.
Go to the active ingredient →Active ingredientTerazosin HClCat. No. P-T056-001CAS 63074-08-8
Active ingredientTerazosin Hydrochloride DihydrateCat. No. P-T056-002CAS 70024-40-7
Pharmacopoeial impurityTerazosin EP Impurity BCat. No. P-T056-004CAS 1177261-73-2
Pharmacopoeial impurityTerazosin EP Impurity CCat. No. P-T056-005CAS 60547-97-9
Pharmacopoeial impurityTerazosin EP Impurity DCat. No. P-T056-006CAS 102714-74-9
Pharmacopoeial impurityTerazosin EP Impurity ECat. No. P-T056-007CAS 102839-00-9
Pharmacopoeial impurityTerazosin EP Impurity FCat. No. P-T056-008CAS 109678-71-9
Pharmacopoeial impurityTerazosin EP Impurity GCat. No. P-T056-009CAS 105356-89-6
Pharmacopoeial impurityTerazosin EP Impurity HCat. No. P-T056-010CAS 105356-90-9
Pharmacopoeial impurityTerazosin EP Impurity ICat. No. P-T056-011CAS 1177261-85-6
Pharmacopoeial impurityTerazosin EP Impurity JCat. No. P-T056-012CAS 152551-75-2
Pharmacopoeial impurityTerazosin EP Impurity L HClCat. No. P-T056-013CAS 60548-09-6
Pharmacopoeial impurityTerazosin EP Impurity MCat. No. P-T056-014CAS 31350-27-3
Pharmacopoeial impurityTerazosin EP Impurity NCat. No. P-T056-015CAS 63074-07-7
Pharmacopoeial impurityTerazosin EP Impurity OCat. No. P-T056-016CAS 547730-06-3
Isotopically labelledN-Nitroso Terazosin EP Impurity N-d8Cat. No. P-T056-017
Isotopically labelledTerazosin EP Impurity L-d8Cat. No. P-T056-018
Isotopically labelledTerazosin EP Impurity N-d8Cat. No. P-T056-019
Isotopically labelledTerazosin Impurity 2-d8Cat. No. P-T056-020
Isotopically labelledTerazosin Impurity 3-d8Cat. No. P-T056-021
Isotopically labelledTerazosin-d8Cat. No. P-T056-022CAS 1006718-20-2
NitrosamineN-Nitroso Terazosin EP Impurity CCat. No. P-T056-024
NitrosamineN-Nitroso Terazosin EP Impurity NCat. No. P-T056-025CAS 2470438-57-2
ImpurityTerazosin Impurity 1Cat. No. P-T056-026CAS 20197-86-8
ImpurityTerazosin Impurity 2Cat. No. P-T056-027CAS 393124-28-2
Impurity6,7-Dimethoxy-2,4-quinazolinediamineCat. No. P-T056-028CAS 60547-96-8
Impurityrac-Terazosin Impurity ICat. No. P-T056-029
ImpurityTerazosin Impurity 3Cat. No. P-T056-031
Pharmacopoeial impurityTerazosin USP Related Compound C DiHClCat. No. P-T056-033CAS 1486464-41-8
ImpurityTetrahydro-2-furancarboxylic acidCat. No. P-T056-034CAS 16874-33-2No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceTerazosin hydrochloride dihydrate CRSEDQM code Y0000621Family TerazosinImpurityTerazosin impurity E CRSEDQM code Y0000665Family TerazosinImpurityTerazosin impurity N CRSEDQM code Y0000624Family TerazosinNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.